[Use of a combined form of prostate extract and alpha-adrenoblocker in patients after transurethral resection of the prostate].

Abstract

Background: Prostate extract has pronounced anti-inflammatory and anti-androgenic properties, which contribute to a reduction in the volume of the prostate and an improvement in urination. Alpha-adrenoblockers, in turn, exert a relaxing effect on the smooth muscles of the bladder and prostate, thereby facilitating the urination. The combined use of these two drugs may provide a synergistic effect, leading to a pronounced improvement in quality of urination and accelerates recovery in patients after transurethral resection of the prostate. This approach may be more effective than using only one of these drugs.

Aim: To investigate the efficiency and safety profile of the prostate extract in combination with tamsulosin in patients after transurethral bipolar resection of the prostate.

Materials and methods: A total of 147 patients with benign prostatic hyperplasia (BPH) of stage II without severe concomitant diseases were included in the clinical study. The age of the men ranged from 48 to 81 years (61.7+/-1.4). All patients underwent transurethral bipolar resection of the prostate. Patients were randomized into two groups. In the main group, men received from the first postoperative day a combination of prostate extract with an alpha-adrenoblocker (prostate extract in powder 50 mg in terms of water-soluble peptides 10 mg and tamsulosin hydrochloride 0.4 mg) in the form of suppository after spontaneous bowel evacuation or enema daily for 30 days (n=70). In the control group, only alpha-adrenoblocker (tamsulosin 0.4 mg once a day for 30 days) in the postoperative period was given (n=77).

Results: In the main group, there was a reduction in the mean total IPSS score by 34.5% (p <0.05), and improvement in quality of life by 52% (p <0.05). The maximum urine flow rate increased by 69% (p <0.05), and the average urine flow rate increased by 94.6% (p<0.05). The positive effect on erectile function was 17.8% (p <0.05).

Conclusions: Our data allow to recommend this drug in the combined treatment of patients with benign prostatic hyperplasia (BPH) after transurethral resection of the prostate to restore urination function and improve quality of life.